• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

SEED Grant Program

The SEED Grant Program: Supporting Excellence, Equity, and Discovery for ALS/MND

ALS/MND affects people in every part of the world. Yet many regions remain significantly under-represented in ALS/MND research — not because the need is less, but because the foundational infrastructure for research participation is still developing.

The SEED (Supporting Excellence, Equity, and Discovery for ALS/MND) Grant Program was created to help change that.

2026 Applications Are Now Closed

Thank you to everyone who applied for the 2026 SEED Grant Program. Applicants will be notified in early November 2026.

Recipients will be publicly announced December 5–6, 2026, at the International Alliance Meeting in Amsterdam.

About SEED

SEED provides early-stage funding to strengthen ALS/MND research infrastructure and readiness in eligible countries. The goal is to support local leaders, institutions, and networks as they build the foundations needed for future ALS/MND research, collaboration, and larger-scale funding.

Up to US$50,000

Available per selected project.

Building Research Readiness

Supporting the people, systems, partnerships, data pathways, and infrastructure needed for ALS/MND research.

Supporting Global Equity

Focused on eligible countries where ALS/MND research infrastructure and capacity are still developing.

Eligible projects focus on practical steps that create, connect, or strengthen the people, systems, partnerships, data pathways, and infrastructure needed for ALS/MND research. Projects may support work in areas including:

  • ALS/MND registries
  • Biobanking preparation
  • Data collection pathways
  • Genetic and epidemiological studies
  • Clinical trial readiness
  • Locally relevant pilot work

Projects may include ALS/MND–FTD overlap if the FTD-related component is directly connected to ALS/MND research readiness. Projects focused only on FTD are outside the scope of the program.

Who Can Apply

SEED is open to:

  • Researchers
  • Clinicians
  • Academic institutions
  • Hospitals and clinics
  • Research networks
  • Multi-site collaborations
  • Regional partnerships

Applications may be submitted by individual organizations or collaborative groups. Collaborations with high-income countries are eligible where they strengthen research readiness, leadership, ownership, and benefit within an eligible country.

SEED welcomes applications from teams at different stages of ALS/MND research readiness, including those building early research capacity and those strengthening emerging networks or infrastructure.

Eligible Countries

SEED supports projects in low-income, lower-middle-income, and upper-middle-income countries based on World Bank country income classifications, or countries designated as Developing Economies (Global South) according to the UN classification.

2026 Key Dates

  • Applications opened: June 21
  • Application deadline: September 1
  • Applicants notified: Late October/early November
  • Public announcement: December 5–6, at the Alliance Meeting in Amsterdam

How Applications Will Be Reviewed

Applications will be reviewed, scored, and ranked by an International Peer Review Panel with expertise in ALS/MND and/or related neurological diseases, and familiarity with ALS/MND research needs in eligible countries.

Applications will be assessed for:

  • Significance and impact
  • Project rationale and design
  • Team capability
  • Project feasibility
  • Capacity-building value
  • Fit with the purpose of the SEED Grant Program

The panel will make funding recommendations based on the quality of applications and the pool of available funds.

SEED recognizes that applicants come from regions with different levels of existing ALS/MND research infrastructure. Reviewers will consider the local starting point, the need being addressed, and whether the proposed work can create measurable progress toward ALS/MND research readiness in that region.

Application Materials

Review the full 2026 application materials for detailed eligibility, funding, and application requirements:

SEED Request for Proposals (PDF) →

SEED Frequently Asked Questions (PDF) →

SEED Budget Template (Excel) →

SEED CV/Biosketch Template (Word) →

SEED Institutional Letter of Support Template (Word) →

Funding Available

Applicants may request up to US$50,000. The total number of awards will depend on available funding and the size of the selected proposals.

The maximum award amount is inclusive of all costs, including direct costs, indirect costs, institutional overheads, and any applicable taxes or fees. Indirect costs, including institutional overheads, may not exceed 5% of the total budget requested.

Applicants do not need to request the maximum amount. Smaller, focused proposals may be appropriate if the project has a clear purpose, a realistic plan, and a measurable outcome.

Supporting the SEED Grant Program

The SEED Grant Program is funded by a group of organizations committed to building ALS/MND research capacity worldwide. ALS Canada and FightMND are the program’s catalyst funders, providing the initial investment that launched SEED. They are joined by the ALS Society of Alberta, ALS Therapy Development Institute, LifeArc, My Name’5 Doddie Foundation, Stichting ALS Nederland and The ALS Association. 

Questions

Please review the application materials and FAQ before reaching out. For questions about eligibility, project fit, application requirements, or budget preparation, contact seed@als-mnd.org.

Primary Sidebar

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Mark Miller, UK

    Mark Miller, UK

  • Anita Forte, USA

    Anita Forte, USA

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • David Watson, Scotland

    David Watson, Scotland

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Liam Dwyer, England

    Liam Dwyer, England

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Philip Brindle, England

    Philip Brindle, England

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Jon Newsome, USA

    Jon Newsome, USA

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Lee Millard, England

    Lee Millard, England

  • Lombana, Spain

    Lombana, Spain

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • JP

    JP

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login